Could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Crohn’s Disease, for each of the following treatments:

Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]

Also, could you please confirm for the last three months (October to December 2019 inclusive if possible) the total biologic caseload for Ulcerative Colitis, for each of the following treatments:

Adalimumab [Amgevita]
Adalimumab [Hulio]
Adalimumab [Humira]
Adalimumab [Hyrimoz]
Adalimumab [Imraldi]
Golimumab [Simponi]
Infliximab [Flixabi]
Infliximab [Inflectra]
Infliximab [Remicade]
Infliximab [Remsima]
Tofacitinib [Xeljanz]
Ustekinumab [Stelara]
Vedolizumab [Entyvio]

If you are unable to answer my questions with breakdown by specified conditions then please provide me with the numbers of patients treated in the last 3 months (October to December 2019 inclusive if possible) with the above drugs, regardless of disease/indication.

Download response Crohn’s Disease and Ulcerative Colitis. 130220